Neurocrine Biosciences, Inc. (NBIX)

Market Cap	12.94B +13.4%
Revenue (ttm)	2.86B +21.4%
Net Income	478.60M +40.2%
EPS	4.67 +41.9%
Shares Out	100.36M
PE Ratio	27.60
Forward PE	16.80
Dividend	n/a
Ex-Dividend Date	n/a

Volume	806,357
Open	132.02
Previous Close	131.64
Day's Range	127.17 - 133.00
52-Week Range	87.70 - 160.18
Beta	0.35
Analysts	Strong Buy
Price Target	180.82 (+40.29%)
Earnings Date	May 4, 2026

About NBIX

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical develo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 23, 1996
• Employees: 2,000
• Stock Exchange: NASDAQ
• Ticker Symbol: NBIX
• Website: https://www.neurocrine.com

Financial Performance

In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.

Analyst Summary

According to 22 analysts, the average rating for NBIX stock is "Strong Buy." The 12-month stock price target is $180.82, which is an increase of 40.29% from the latest price.

Price Target

$180.82

(40.29% upside)

Analyst Consensus: Strong Buy